PDF factsheet
      Z

EGFR inhibitors in lung cancer (metastatic) for first line, clinical trials results

gefitinib versus carboplatin-paclitaxel
NEJ002, 2013

versus
chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations
IPASS (Mok), 2009
NCT00322452

versus
previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers
gefitinib versus carboplatin/paclitaxel
IPASS,

versus
previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma
gefitinib versus gemcitabine and cisplatin
First Signal,
gefitinib (250 mg daily)
versus
GP chemotherapy (gemcitabine 1,250 mg/m(2) on days 1 and 8; cisplatin 80 mg/m(2) on day 1 every 3 weeks, for up to nine courses
first-line therapy of never-smokers with adenocarcinoma of the lung
gefitinib versus vinorelbine
INVITE (Crinò), 2008
NCT00256711

versus
chemotherapy-naive elderly patients with advanced non-small-cell lung cancer
gefitinib paclitaxel and carboplatin versus paclitaxel and carboplatin
INTACT 2, 2004
gefitinib plus paclitaxel and carboplatin
versus
paclitaxel 225 mg/m(2) and carboplatin area under concentration/time curve of 6 mg/min/mL (day 1 every 3 weeks)
chemotherapy-naive patients with advanced NSCLCdouble-blind
gefitinib + gemcitabine/cisplatin versus placebo + gemcitabine / cisplatin
INTACT 1.,
gefitinib 500 mg/d, gefitinib 250 mg/d,
versus
placebo
chemotherapy-naive patients with unresectable stage III or IV NSCLCdouble blind
osimertinib versus placebo
FLAURA, 2017
NCT02296125
osimertinib (AZD9291) (80 mg or 40 mg orally, once daily)
versus
first-line standard-of-care treatment erlotinib or gefitinib
previously untreated patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation–positive non–small cell lung cancerdouble-blind

  Options


in first

in second

  Filter